Pharming Group (OTCMKTS:PHGUF) Shares Gap Up – Here’s What Happened

Pharming Group NV (OTCMKTS:PHGUF)’s stock price gapped up prior to trading on Monday. The stock had previously closed at $0.9285, but opened at $1.26. Pharming Group shares last traded at $1.26, with a volume of 1,000 shares traded.

Pharming Group Stock Performance

The firm has a 50 day moving average price of $1.06 and a 200-day moving average price of $1.38. The company has a debt-to-equity ratio of 0.39, a quick ratio of 2.31 and a current ratio of 3.01. The company has a market cap of $845.55 million, a P/E ratio of 39.39 and a beta of 0.45.

Pharming Group (OTCMKTS:PHGUF) last announced its earnings results on Tuesday, October 27th. The biotechnology company reported $0.03 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.02 by $0.01. The firm had revenue of $117.60 million during the quarter, compared to analysts’ expectations of $117.60 million. Pharming Group had a return on equity of 8.85% and a net margin of 6.23%.

About Pharming Group

Pharming Group N.V. is a commercial-stage biopharmaceutical company headquartered in Leiden, the Netherlands. The company develops and commercializes medicines for rare diseases and conditions with limited treatment options, with a focus on therapies that address unmet medical needs.

Pharming’s principal product is Ruconest, a recombinant C1 esterase inhibitor used to treat acute attacks of hereditary angioedema, a rare genetic disorder that can cause potentially severe swelling. The company also markets Joenja (leniolisib), an oral treatment for activated phosphoinositide 3-kinase delta syndrome, a rare primary immunodeficiency and immune dysregulation disorder.

Founded in 1988, Pharming has developed a commercial presence in the United States and Europe and works with regional partners and distributors in selected international markets.